A 6-month Multicenter, Single-arm, Open-label Study to Investigate Changes in Biomarkers After Initiation of Treatment With 0.5 mg Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis.
Phase of Trial: Phase IV
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- Acronyms BioBank
- Sponsors Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 03 May 2014 Results for the effect of body mass index on outcomes presented at the 66th Annual Meeting of the American Academy of Neurology.
- 04 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History